Hims & Hers gains on partnership with Eli Lilly

What happened

Hims & Hers and Eli Lilly announced a partnership to offer Lilly’s weight-loss drugs Zepbound and Foundayo through Hims & Hers to eligible cash-paying patients, at the same self-pay prices as LillyDirect, if a licensed provider on the platform prescribes the medicine.

Confirmed

Global impact / market context

The deal gives Hims & Hers another route to attract patients seeking weight-loss medicines, while Lilly gains access to the platform’s users. If prescriptions and purchases follow, sales could grow for both companies; the extent depends on patient demand and providers’ prescribing decisions.

Analyst inference

Lilly already sells medicines directly to self-paying patients through LillyDirect, and Hims & Hers has a similar arrangement with Novo Nordisk. The new partnership adds another channel for Lilly’s drugs, with prices starting at $149 monthly for Foundayo and $299 for Zepbound.

Confirmed

What to watch

1. Watch whether Hims & Hers reports patient uptake or prescription activity for Zepbound and Foundayo; those measures would show whether the partnership translates into meaningful demand. Analyst inference
2. Track whether eligible patients can access both medicines through licensed Hims & Hers providers at the stated self-pay prices, as the agreement describes. Confirmed
3. Compare future disclosures about this Lilly arrangement with Hims & Hers’ Novo Nordisk partnership to assess whether the added drug options expand sales or shift demand between offerings. Analyst inference

Evidence

• seekingalpha.com